-
Signature
-
/s/ Craig B. Granowitz, M.D., Ph.D.
-
Issuer symbol
-
LXRX
-
Transactions as of
-
28 Feb 2026
-
Net transactions value
-
-$160,374
-
Form type
-
4
-
Filing time
-
03 Mar 2026, 07:19:33 UTC
Quoteable Key Fact
"Craig B. Granowitz filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 03 Mar 2026."
Quick Takeaways
- This page summarizes Craig B. Granowitz's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 7 reported transactions and 3 derivative rows are listed below.
- Filing timestamp: 03 Mar 2026, 07:19.
What Changed
- Previous filing in this sequence was filed on 17 Feb 2026.
- Current net transaction value: -$160,374.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Granowitz Craig B |
SVP, Chief Medical Officer |
2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS |
/s/ Craig B. Granowitz, M.D., Ph.D. |
03 Mar 2026 |
0001876655 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
LXRX |
Common Stock |
Options Exercise |
|
+35,790 |
+30% |
|
156,042 |
28 Feb 2026 |
Direct |
F1 |
| transaction |
LXRX |
Common Stock |
Options Exercise |
|
+74,226 |
+48% |
|
230,268 |
28 Feb 2026 |
Direct |
F1 |
| transaction |
LXRX |
Common Stock |
Options Exercise |
|
+202,260 |
+88% |
|
432,528 |
28 Feb 2026 |
Direct |
F1 |
| transaction |
LXRX |
Common Stock |
Tax liability |
$160,374 |
-109,098 |
-25% |
$1.47 |
323,430 |
28 Feb 2026 |
Direct |
F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
LXRX |
Restricted Stock Units |
Options Exercise |
|
-35,790 |
-100% |
|
0 |
28 Feb 2026 |
Common Stock |
35,790 |
|
Direct |
F1, F3 |
| transaction |
LXRX |
Restricted Stock Units |
Options Exercise |
|
-74,226 |
-50% |
|
74,227 |
28 Feb 2026 |
Common Stock |
74,226 |
|
Direct |
F1, F3 |
| transaction |
LXRX |
Restricted Stock Units |
Options Exercise |
|
-202,260 |
-33% |
|
404,520 |
28 Feb 2026 |
Common Stock |
202,260 |
|
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses: